Immune cells participate in the oncosuppressive activity of parvovirus H-1PV and are activated as a result of their abortive infection with this agent - PubMed (original) (raw)
. 2010 Dec 15;10(12):1280-9.
doi: 10.4161/cbt.10.12.13455. Epub 2010 Dec 15.
Affiliations
- PMID: 21124075
- DOI: 10.4161/cbt.10.12.13455
Immune cells participate in the oncosuppressive activity of parvovirus H-1PV and are activated as a result of their abortive infection with this agent
Svitlana Grekova et al. Cancer Biol Ther. 2010.
Abstract
Treatment of cancers by means of viruses, that specifically replicate in (oncotropism) and kill (oncolysis) neoplastic cells, is increasingly gaining acceptance in the clinic. Among these agents, parvoviruses have been shown to possess not only direct oncolytic but also immunomodulating properties, serving as an adjuvant to prime the immune system to react against infected tumors. Here, we aimed to establish whether immunomodulating mechanisms participate in the recently reported therapeutic potential of parvoviruses against pancreatic carcinoma. Using adoptive transfer experiments we discovered that the transfer of splenocytes of donor rats harboring H-1PV-treated orthotopic PDAC tumors could significantly prolong the survival of naïve tumor-bearing recipients, compared to those receiving cells from mock-treated donors. Closer investigation of immunological parameters in infected donor rats revealed that virus-induced interferon gamma production and cellular immune response played an important role in this effect. These data have also preclinical relevance since abortive H-1PV infection of human peripheral blood mononuclear cells or cocultivation of these cells with H-1PV-preinfected pancreatic cancer cells, resulted in enhancement of innate and adaptive immune reactivity. Taken together our data reveal that oncolytic H-1PV modulates the immune system into an anticancer state, and further support the concept of using parvoviruses in the fight against pancreatic cancer.
Similar articles
- Interferon γ improves the vaccination potential of oncolytic parvovirus H-1PV for the treatment of peritoneal carcinomatosis in pancreatic cancer.
Grekova SP, Aprahamian M, Daeffler L, Leuchs B, Angelova A, Giese T, Galabov A, Heller A, Giese NA, Rommelaere J, Raykov Z. Grekova SP, et al. Cancer Biol Ther. 2011 Nov 15;12(10):888-95. doi: 10.4161/cbt.12.10.17678. Epub 2011 Nov 15. Cancer Biol Ther. 2011. PMID: 22024742 Free PMC article. - Combined oncolytic and vaccination activities of parvovirus H-1 in a metastatic tumor model.
Raykov Z, Grekova S, Galabov AS, Balboni G, Koch U, Aprahamian M, Rommelaere J. Raykov Z, et al. Oncol Rep. 2007 Jun;17(6):1493-9. Oncol Rep. 2007. PMID: 17487410 - Enhancement of NK cell antitumor responses using an oncolytic parvovirus.
Bhat R, Dempe S, Dinsart C, Rommelaere J. Bhat R, et al. Int J Cancer. 2011 Feb 15;128(4):908-19. doi: 10.1002/ijc.25415. Int J Cancer. 2011. PMID: 20473905 - H-1 Parvovirus as a Cancer-Killing Agent: Past, Present, and Future.
Bretscher C, Marchini A. Bretscher C, et al. Viruses. 2019 Jun 18;11(6):562. doi: 10.3390/v11060562. Viruses. 2019. PMID: 31216641 Free PMC article. Review. - Oncolytic parvoviruses as cancer therapeutics.
Rommelaere J, Geletneky K, Angelova AL, Daeffler L, Dinsart C, Kiprianova I, Schlehofer JR, Raykov Z. Rommelaere J, et al. Cytokine Growth Factor Rev. 2010 Apr-Jun;21(2-3):185-95. doi: 10.1016/j.cytogfr.2010.02.011. Epub 2010 Mar 7. Cytokine Growth Factor Rev. 2010. PMID: 20211577 Review.
Cited by
- H-1 Parvovirus-Induced Oncolysis and Tumor Microenvironment Immune Modulation in a Novel Heterotypic Spheroid Model of Cutaneous T-Cell Lymphoma.
Angelova A, Barf M, Just A, Leuchs B, Rommelaere J, Ungerechts G. Angelova A, et al. Cancers (Basel). 2024 Jul 30;16(15):2711. doi: 10.3390/cancers16152711. Cancers (Basel). 2024. PMID: 39123440 Free PMC article. - Human Retrotransposons and the Global Shutdown of Homeostatic Innate Immunity by Oncolytic Parvovirus H-1PV in Pancreatic Cancer.
Neulinger-Muñoz M, Schaack D, Grekova SP, Bauer AS, Giese T, Salg GA, Espinet E, Leuchs B, Heller A, Nüesch JPF, Schenk M, Volkmar M, Giese NA. Neulinger-Muñoz M, et al. Viruses. 2021 May 28;13(6):1019. doi: 10.3390/v13061019. Viruses. 2021. PMID: 34071585 Free PMC article. - Induced Autophagy of Macrophages and the Regulation of Inflammatory Effects by Perovskite Nanomaterial LaNiO3.
Wei Y, Gao X, Zhao F, Baimanov D, Cong Y, Jiang Y, Hameed S, Ouyang Y, Gao X, Lin X, Wang L. Wei Y, et al. Front Immunol. 2021 Apr 22;12:676773. doi: 10.3389/fimmu.2021.676773. eCollection 2021. Front Immunol. 2021. PMID: 33968087 Free PMC article. - Parvovirus-Based Combinatorial Immunotherapy: A Reinforced Therapeutic Strategy against Poor-Prognosis Solid Cancers.
Angelova A, Ferreira T, Bretscher C, Rommelaere J, Marchini A. Angelova A, et al. Cancers (Basel). 2021 Jan 19;13(2):342. doi: 10.3390/cancers13020342. Cancers (Basel). 2021. PMID: 33477757 Free PMC article. Review. - Immune Conversion of Tumor Microenvironment by Oncolytic Viruses: The Protoparvovirus H-1PV Case Study.
Marchini A, Daeffler L, Pozdeev VI, Angelova A, Rommelaere J. Marchini A, et al. Front Immunol. 2019 Aug 7;10:1848. doi: 10.3389/fimmu.2019.01848. eCollection 2019. Front Immunol. 2019. PMID: 31440242 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources